SSG
EBS icon

Summit Securities Group’s Emergent Biosolutions EBS Stock Holding History

Summit Securities Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$10K – 1207
2022
Q3 		$10K Hold
500
– – ﹤0.01% 787
2022
Q2 		$16K Buy
+500
New +$17.1K ﹤0.01% 793

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's EBS Position: Q4 2023 in Review

Summit Securities Group sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 3,612 shares — an estimated $12K sold.

Summit Securities Group first reported a position in EBS in Q1 2015 and held it in 3 quarters. The position peaked at $486K in Q4 2015. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.

  • Summit Securities Group reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
  • Summit Securities Group sold 3,612 Emergent Biosolutions shares in Q4 2023, an estimated $12K.
  • Summit Securities Group first reported a position in Emergent Biosolutions in Q1 2015 and held it in 3 quarters.
  • Summit Securities Group's Emergent Biosolutions position peaked at $486K in Q4 2015.
  • 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.

Based on Summit Securities Group's 13F filing for Q4 2023, filed 14 Feb 2024.